This is a summary of the European public assessment report (EPAR) for Zoledronic acid Actavis. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Actavis.
Therapeutic Indication
### Therapeutic indication Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia.
Therapeutic Area (MeSH)
N/AATC Code
M05BA08
ATC Item
zoledronic acid
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| zoledronic acid monohydrate | N/A | 唑来膦酸 |
EMA Name
Zoledronic acid Actavis
Medicine Name
Zoledronic acid Actavis
Aliases
N/ANo risk management plan link.
